Stay updated on A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Revision: v3.4.2 is now displayed on the page, replacing the previous Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T01:17:35.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    Revision history updated: Revision: v3.4.1 was added and Revision: v3.4.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-05T00:55:05.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    Added a glossary toggle and updated study record metadata to include 'Last Update Submitted that Met QC Criteria' and a new revision label (Revision: v3.4.0). Removed or reformatted older QC-related text such as 'Last Update Submitted that met QC Criteria' and 'No FEAR Act data'.
    Difference
    0.2%
    Check dated 2026-01-28T21:15:48.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    The page revision was updated from v3.3.3 to v3.3.4, with no changes to study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T04:16:30.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    Locations now include Louisville, Kentucky, indicating an added study site. The HHS Vulnerability Disclosure link in the footer has been removed.
    Difference
    0.2%
    Check dated 2025-12-23T22:37:02.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    Revision: v3.3.2 appears at the top of the page, replacing v3.3.1; there are no changes to the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T11:45:06.000Z thumbnail image

Stay in the know with updates to A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.